weight loss on glp-1 Agonists Drugs Market Report, 2025-2030 GLP-1 and weight loss injections

By placing the order, I understand and agree that my cart includes a digital Vitality Club membership with a 7-day free trial

Long-term safety remains a central question

The programme spans multiple trials targeting distinct endpoints: On 21 May 2026 Eli Lilly reported topline results from TRIUMPH-1, the pivotal Phase 3 obesity trial and the programme's first Phase 3 efficacy readout: in 2,339 adults, mean weight loss at the 80-week primary endpoint reached 19.0% (4mg), 25.9% (9mg), and 28.3% (12mg) versus 2.2% for placebo (Eli Lilly investor release

It was safe enough to survive, but its notorious gastrointestinal side effectsoily stools and fecal urgencylimited adherence

How Mochi Health Supports Our Patient's Weight Loss Journey At Mochi Health, we are dedicated to helping you achieve and maintain your weight loss goals